Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
· Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study population · Positive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys · Demonstrated favourable safety, consistent with established profile · Companies plan to submit data for regulatory approval in the US and EU Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced positive topline results from